PipelineReview.com13 天
Ractigen’s RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data ...
NANTONG, China and MELBOURNE, Australia I March 24, 2025 I Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA ...
Clinical Trials Arena on MSN12 天
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...
pharmaphorum13 天
MiNA’s gene-activating tech wins an AstraZeneca alliance
UK biotech MiNA Therapeutics’ RNA-based gene-activating technology has caught the eye of big pharma AstraZeneca. AZ has teamed up with the London-based startup to develop its small, activating ...
Fox 44 Waco News13 天
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data ...
NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today ...
Business Wire17 天
MiNA Therapeutics Appoints Norbert Bischofberger, Ph.D., to its Board as Non-Executive ...
LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, has appointed Norbert Bischofberger, Ph.D., as a Non-Executive Director to its Board of ...